Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1.

The next round of pre-clinical trials focuses on the beneficial or adverse health extracts of the compound, with the trial referred to as a conditioned placement preference study. The study itself reportedly works by comparing characteristics of the association of the extract in an environment, to the association in another environment without the extract.

Effectively, the study will look into whether the compound developed by Psyched has any abuse potential. The trial is a means of determining whether psychological or physical dependence of the substance can be formed around the extract.

“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” commented David Shisel, COO of Psyched Wellness.

Psyched Wellness last traded at $0.135 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Verses Hits Commercialization Stage With Genius AI Platform

Related News

Psyched Wellness Attracts Major Investment

Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode...

Friday, June 9, 2023, 01:30:00 PM

Psyched Wellness Commences 90-Day Toxicity Study Of AME-1

Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom...

Monday, June 28, 2021, 08:55:03 AM

Psyched Wellness Submits Trademark For Amanita Muscaria Extract

Psyched Wellness (CSE: PSYC) is looking to build up its portfolio of intellectual property. The...

Thursday, January 21, 2021, 07:01:48 AM

David Nutt: Amanita Muscaria Due For More Research – The Daily Dive

Today on the Daily Dive, our host Cassandra Leah sits down with Dr David Nutt,...

Wednesday, March 10, 2021, 01:30:00 PM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM